<DOC>
	<DOCNO>NCT02206243</DOCNO>
	<brief_summary>The purpose observational study evaluate prostatic arterial embolization ( PAE ) Embozene® Microspheres ( Boston Scientific ) sphere size 250 µm treatment symptomatic benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Embozene® Microspheres Prostatic Arterial Embolization Patients With Symptomatic Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>EmboProstate observational study collect data patient benign prostatic hyperplasia treat 250 µm Embozene ® Microspheres ( Boston Scientific ) . The study evaluate efficacy safety microspheres prostatic arterial embolization benign prostata hyperplasia treatment . 10 adult male subject enrol study . If eligible patient recruit , undergo prostate artery embolization procedure radiology department . Once catheter place prostate artery , fluid contain thousand tiny particle ( microspheres ) inject catheter small artery nourish prostate . The injected embospheres slow blood flow prostate reduce urinary tract symptom cause BPH . Within one week PAE well one , three six month post-procedure MRI examination ill occur . A follow-up visit use questionnaire due 6 month .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>male adult &gt; 40 year old severe symptomatic BPH IPSS &gt; 12 and/or maximum urinary flow rate ( Qmax ) &lt; 15ml /sec transurethral catheter retention improvement , intolerance , medical treatment female le 40 year old suspicion prostatic malignancy ( e.g . PSA≥4 without prostate biopsy ) prostatic malignancy acute prostatitis hydronephrosis major surgery within 4 week prior screen visit active clinically serious infection progressive arteriosclerosis contraindication angiography</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
</DOC>